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NON-MYELOABLATIVE ALLOGENIC STEM CELL TRANSPLANT (NASCT) 
WITH UNRELATED CORD BLOOD AND MATCHED FAMILY DONORS IN 
CHILDREN AND ADOLESCENTS 
Satwmfi, P.; Ita~v'isoJ~, L.; De/Tovo, G.; Bt'adley, 3/[.; Yamashi~'o, D.; 
Ggr~vin, .7.; Skd*dtt, D.; CheTtng, }~; vcm de Ue'n, C.; Besmze~'tjzy, 04 
HTischhover, C.; ~'Vo]o~11i~', K.; Geo'~'ge, D.; Cairo, IV[.S. ChilclreJT's 
Hospital of New Ym'te PresbyteHm~, New Yo1"k, NK 
NASCTs are successful in establishing durable grafts from both 
matched family and unrelated adult donors while substantially reduc- 
ing regimen related toxicity (Slavin et al, Blood: 99:1071, 2002; 
Chakravarty et al, Blood: 99:1071, 2002). There is little information 
about NASCT from UCB donor sources, which have a log less 
nuc/kg and CD34/kg. ~vVe report preliminary data in 11 recipients 
(<21 yrs) of NASCT. HLA typing was performed by serology class I 
(A&B) and high resolution DNTA typing class II (DRBI). Chianerism 
was performed by VNTR (D1580, D1757, D151 I, APO B) (Luhm et 
aI, Mol Diag 5; 129, 2000). Donor sources: 7 UCB (5 4/6, 2 5/6), 1 
Allo BM (6/6) and 3 Allo PBSC (2 6/6, i 5/6). NA conditioning: Flu 
150 mg/m 2, IV Bu 8 mg/kg and ATG 8 mg/kg (N=6); Flu 180 
mg/m ~, Bu 8-I6 mg/kg, alemtuzumab 54 mg/m 2 (N=2); Flu 150 
mg/m e, Cy 120 mg/kg, ATG 8 mg/kg (N=I); Flu 150 mg/m 2, Cy 600 
mg/m ~, ATG 8 mg/kg (N= 1 ); Flu 150 mg/m -~, Mel 140 mg/m 2, ATG 
(H) 90 mg/kg (N-I). GVHD prophylaxis: IV Tacrolimus 0.03 
mg/kg/day and mycophenolate mofetil 15 mg/kg q 12 hr. Demo- 
graphics: median age 13 (0.5-21) yrs; 4F, 7M; 2 CR2 HD, 1 PR2 HD, 
1 PD HD, 1 PR NHL, 1PD neuroblastoma, 1 PD ~tihns', 2 B-Thai, 
i WAS, 1 CP CML. UCB median uc/kg and CD34/kg 5.1 x 107/kg 
(1.6-9.5) and 2.1 x 105/kg (1.1-4.8), respectively. Allo BM/PBSC 
CD34/kg was 5.6 x 106/kg (5.0-6.3). Median time to ANC >500/mm 3 
x 2 D was 15 (3-29) days and platelet >20 Wmm* UNTX x 7 D was 22 
(6-170) days. Maximal donor chimerism following UCBT was 100% 
x 4 pts, 95% x 1 pt, 95% (2nd graft) x 1 pt, and 55% x 1 pt (died of 
PD day +79); AlloPBSC 100% x 3 pts and AlloBM 55% x 1 pt (day 
+60). Grade 1V Tox: 1 hepatic (LFTs, resolved), 1 encephalopathy 
(death), and 1 grade III-IV AGVHD (death). Infectious complica- 
tions: 6 bacterial sepsis (resolved), 1 systemic candidiasis (resolved), 
GI adenovirus (persistent) and 1 pulmonary adenovirus (death). Inci- 
dence of grade II-IV and III-1V AGVHD was 54.4% and 27.3%, 
respectively, and CGVHD was 9. 1%. Graft failure occurred in 1/11 
(B-Thal) (UCBT) that was successfully regrafted following full abla- 
tion. Probabilty of 1-yr overall survival is 60%. In sumnaary, these 
results uggest that NASCT especially from UCB HLA disparate 
donors in children and adolescent is feasible and tolerable (<10% GF) 
and restllts in 100% of patients having >50% mixed donor chimerism. 
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HLA-IDENTICAL ALLOGENEIC PERIPHERAL BLOOD STEM CELL 
TRANSPLANTATION IN HOMOZYGOUS [3 THALASSEMIA AND SEVERE 
THALASSEMIA/HEMOGLOBIN E DISEASE PATIENTS 
Pakaleasama, S.; Ho~ge~g, S.; ChaMHpoomkere, Fk~; ChuaT~smtrvit, 
A.; Sirachainmz, N.; ffoota*, S. Ramat/aibodi Hospital, Mahidol U~ive'm 
sity, Rajthevi, BaJgkok, Thai/mzd. 
Background: Thalassemia s the most common genetic disease in 
Thailand. Curative treatment with allogeneic bone marrow and 
cord blood transplantation has been reported. However, peripher- 
al blood stem cell transplantation (PBSCT) data in this disease is 
limited. Objective: To determine the outcome of 13 thalassemia 
major patients who underwent HLA-identical allogeneic PBSCT. 
Methods: We conducted a cohort study of allogeneic PBSCT in 
homozygous [3([3/13) thalassemia and severe 13 thalassemia/Hemo- 
globin E ([3/E) disease patients who had HLA-matched sibling 
donors. All patients received conditioning regimen including 
busulfan and cyclophosphamide (BU/CTX) except one received 
BU/CTX and antithymocyte globulin. Acute GVHD prophyla~s 
consisted of cyclosporin A (CSA) and methotrexate for 8 patients 
and CSA and mycophenolate motifil for 1 patient. Donors 
received G-CSF for 4 days before lenkapheresis collection. 
Results: Five 13/[3 and four severe [3/E diseases patients were stud- 
ied. The median age was 10 years (1.5 to 11 years). The median 
CD 34+ cells was 8.48 x 106 cells/kg recipient body weight. M1 
patients achieved myeloid and platelet engraftment with a median 
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time of 15 days and 21 days respectively. Acute GVHD grade II- 
IV appeared in four patients (grade II = 3, grade IV = 1). Three 
patients developed chronic GVHD (limited = I, extensive = 2). All 
patients were alive with a median follow up time of i8 months (2- 
47 months). Neither graft failure nor graft rejection was observed 
in this study. Conclusion: Allogeneic PBSCT is feasible for chil- 
dren with 13 thalassemia major although GVHD was apparently 
high compared to BMT studies in Thais. 
207 
ALLOGENEIC BONE MARROW TRANSPLANTATION FOR CHILDREN 
WITH HEMATOLOGIC MALIGNANCIES 
Hale, G.A.; Cumm~g-hall~, ff.31.; Be71aim, E.; Heslop, H.E.; R)',n~ce, 
R.A.; Horwitz, E.M.; ToJTg, X.; SHvastava, D.K.; Leltng, ~'K; 
Woo&J'd, J.P.; Bowmml, L.C.; Ha,ldgvet#zgel, R. Hematology/OJ~colo- 
go;, St. Jade Child'lw~ 's Resemvh Hospital, Memphis, TN. 
Allogeneic BMT is potentially curative }'or patients with high 
risk or recurrent hematologic malignancy, in this series, we report 
249 children with ALL, AML, CML, or MDS who underwent 
allogeneic BMT at St. Jude Children's Research Hospital between 
1992-2000. The nmdian age at BMT was 11.2 years; 22 had 
received a prior autograft. 86 patients received unrelated onor 
(MUD) grafts matched at 6 HLA loci, 48 MUD grafts matched at 
5 HLA loci, 84 matched sibling (MSD) grafts and 31 mismatched 
family member (MMFM) grafts. The conditioning regimen 
included cytarabine, cyclophophamide, total body irradiation. 
ATG was provided to enhance the immunosuppression f r recipi- 
ents of MUD and MMFM grafts. MUD and MMFM grafts were 
depleted of T-lymphocytes using antibodies against CD6 and 
CD8 with rabbit complement. Grafts fi'om MSD were unmanipn- 
lated. Cyclosporine GVHD prophylaxis was given to all patients, 
and pe~toxifylline or short-course methotrexate was provided to 
MSD graft recipients. The cumulative incidence of grade 2-4 
acute GVHD was 23%; the cumulative chronic GVHD was 17%. 
The two year probability of disease-free (DFS) and overall sur- 
vival (OS) were 44% and 47%, respectively. The cumulative inci- 
dence of relapse was 25%; the cumulative incidence of regimen- 
related mortality was 35%. Favorable prognostic factors for OS 
included a diagnosis of CML, not having a secondary malignancy, 
receiving agraft matched at HLA class 1, younger patient age, and 
lower T-cell graft content. Favorable prognostic factors for DFS 
included not having a second malignancy, receiving a graft 
matched at HLA class I, and lower T-cell graft content. Probabil 
ities of DFS by donor status were as follows: MSD 46.8%, MUD 
matched at 6 HLA loci 46.2%, MUD matched at 5 HLA loci 
31.2%, and MMFM 25.4% (p=0.026). Recipients of MSD and 
MUD grafts matched at 6 HLA loci had similar outcomes; recipi- 
ents of NIMFM grafts and MUD grafts matched at 5 HLA loci 
had similar outcomes. These results suggest that MMFM donors 
may be preferred over MUD grafts matched at 5 HLA loci for 
patients lacking a MSD or MUD matched at 6 HLA loci. 
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A LIMITED SAMPLING STRATEGY (LSS) TO TARGET SYSTEMIC EXPO- 
SURE (SE) OF BUSULFEX (BUSULFAN) INJECTION (IVBU) IN PEDI- 
ATRIC PATIENTS (PEDS) 
Lem~oJT, S J; Fuller, D J; Booth, B.2; Rahman, A.2; Gobbm% ft.:; Lai, 
A. ~ 1. Orpha'~7 Medical, bzc., Mi~metotlka, ll4N,. 2. CeJTt~-e for D~Ttg 
Evaktation m~d Research, Food aJzd Drug Admhzist~'ation, Rockville, 
MD; 3. CPKD Sohttio~Ts, Resea~'ch Triangle Park, NC. 
PURPOSE: A clinical trial of 1VBU (BuCy4) in 24 peds used 
initial IVBU doses of 1.0 or 0.8mg/kg for ages < 4y or >4y, respec- 
tively Q.6 hrs x 4 days. Full pharmacokinetic (PK) profiling and a 
single dose adjustment (when necessary) were used to target SE to 
900 - 1350 raM.rain. This full-sampling approach allowed ~90% 
patients to achieve target SE at steady state. The purpose was to 
further analyze these data to refine the dosing strategy and to 
develop a LSS to achieve the target 1VBU SE. METHODS: PK 
modeling yielded a 2-dose level mg/kg regimen: <= 12 kg dosed at 
1.1 mg/kg, >12 kg dosed at 0.8 mg/kg. Modeled area-under-the- 
curve data (AUC) for Doses 1 and 9 were compared to AUC esti- 
mated from a LSS. The LSS used 3 time-points for Dose 1 (2hr - 
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